Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    FSA_thumbnail
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

    thumbnail
    ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Social media image
ICON Plc logo
ICON Plc

If 2025 proved anything for HTA developers, it’s that PICO complexity is real. The first operational JCAs confirmed that navigating diverse standards of care across EU Member States creates continued uncertainty for spon...

7 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

If 2025 proved anything for HTA developers, it’s that PICO complexity is real. The first operational JCAs confirmed that navigating diverse standards of care across EU Member States creates continued uncertainty for spon...

7 Apr
1
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Central monitoring and on-site monitoring are often positioned as competing approaches. In reality, both play a critical role in how modern trials are delivered. As studies become more complex, the focus is shifting tow...

7 Apr
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Central monitoring and on-site monitoring are often positioned as competing approaches. In reality, both play a critical role in how modern trials are delivered. As studies become more complex, the focus is shifting tow...

7 Apr
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Attending the GLP-1-Based Therapeutics Summit? Meet the ICON team to learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese healthy volunteers and...

7 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP-1-Based Therapeutics Summit where he will be speaking on “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He’ll c...

7 Apr
1
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our ...

6 Apr
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON’s Patient Centred Outcomes team advanced key research in 2025, with over 45 highly experienced specialists supporting programmes across major therapy areas. With twelve peer‑reviewed papers, two educational events...

6 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON’s Patient Centred Outcomes team advanced key research in 2025, with over 45 highly experienced specialists supporting programmes across major therapy areas. With twelve peer‑reviewed papers, two educational events...

6 Apr
2
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

During World Parkinson’s Awareness Month, we recognise the urgency of advancing research that can improve outcomes for people living with Parkinson’s disease. ICON has supported numerous neurodegeneration programmes, he...

6 Apr
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON is pleased to participate in the upcoming PharmaSUG India Single Day Event, taking place on 11 April at the Eli Lilly office in Bangalore. Madhan Kumar, Statistical Programmer II, will deliver a presentation titled...

6 Apr
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

ICON is pleased to participate in the upcoming PharmaSUG India Single Day Event, taking place on 11 April at the Eli Lilly office in Bangalore. Madhan Kumar N., Statistical Programmer II, will deliver a presentation tit...

6 Apr
2
View post
View webpage
  • 1
  • 2
  • 3
  • …
  • 94
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence